In addition, a medium dose of Ganweikang tablet significantly reduced the increase in liver fibrosis indicators, including TGF-β1, Timp-1, Col1α1, and Col1α2 in NASH mice (Figure 5B). This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatohepatitis.